CareLit · DOI-Nachweis · Pneumologie
Effect of FEV1/FVC ratio on reduction in FVC decline with nintedanib in the INPULSIS™ trials
DOI 10.1055/s-0035-1544830
Bibliografische Angaben
Nachweis in CareLit
Autor:innenU Costabel, M Kolb, Y Inoue, P Hernandez, Z Bailes, R Schlenker-Herceg, A Azuma
ZeitschriftPneumologie
Ausgabe02/2015
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: The two replicate randomized, placebo-controlled, 52-week Phase III INPULSIS™ trials assessed the efficacy and safety of nintedanib 150 mg twice daily in patients with IPF. Patients with an FEV1/FVC ratio of < 0.7 were excluded. Compared with placebo, nintedanib slowed disease progression by significantly reducing the annual rate of decline in forced vital capacity (FVC), the primary endpoint, in both tr…
Zitieren
Zitierempfehlung
U Costabel, M Kolb, Y Inoue, P Hernandez, Z Bailes, R Schlenker-Herceg, A Azuma (2015) Effect of FEV1/FVC ratio on reduction in FVC decline with nintedanib in the INPULSIS™ trials. Pneumologie (02). https://doi.org/10.1055/s-0035-1544830
Mit CareLit weiterarbeiten